Literature DB >> 7017565

Studies on group B beta-hemolytic Streptococcus. I. Isolation and partial characterization of an extracellular toxin.

C G Hellerqvist, J Rojas, R S Green, S Sell, H Sundell, M T Stahlman.   

Abstract

To initiate an investigation into the biochemistry and mechanism of group B beta-hemolytic Streptococcus virulence, bacterial cultures grown in suspension were centrifuged, and the bacteria and media were subjected to extensive fractionation. Each fraction was assayed for physiologic activity by repeated intravenous infusion into adult unanesthetized sheep. Pulmonary artery pressure, arterial PO2, and rectal temperature were monitored. The media fraction, but not the bacteria, contained a component (molecular weight, 2 x 10(6)) composed of 845 carbohydrate and 16% protein with physiological activity. Two mg quantities, when infused, caused the pulmonary artery pressure to increase 100%, PO2 to decrease by 20% and chills and fever. The active component could be degraded by hot phenol-water extraction into a pure polysaccharide (molecular weight, 200,000). This lower molecular weight polysaccharide retained the identical physiologic properties when infused in the sheep. The degraded component precipitated with group B-specific antiserum. This study demonstrates that, in the sheep, a pure polysaccharide is the physiologically active part of a high-molecular-weight toxin synthesized by group B beta-hemolytic Streptococcus type III and that this component has a different carbohydrate composition from the group B capsular antigen.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7017565     DOI: 10.1203/00006450-198106000-00002

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  14 in total

Review 1.  Group B Streptococcus, phospholipids and pulmonary hypertension.

Authors:  J Curtis; G Kim; N B Wehr; R L Levine
Journal:  J Perinatol       Date:  2011-04       Impact factor: 2.521

2.  Stimulation of complement component C3 synthesis in macrophagelike cell lines by group B streptococci.

Authors:  K J Goodrum
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

3.  Acute inflammatory changes in subcutaneous microtumors in the ears of mice induced by intravenous CM101 (GBS toxin).

Authors:  G B Thurman; D L Page; B D Wamil; L E Wilkinson; M Kasami; C G Hellerqvist
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Group B streptococcal phospholipid causes pulmonary hypertension.

Authors:  Jerri Curtis; Geumsoo Kim; Nancy B Wehr; Rodney L Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

5.  Possible induction of disseminated intravascular coagulation in the mouse by group B streptococcal clumping factor.

Authors:  Y Usui; Y Ichiman; K Yoshida; K Oikawa
Journal:  Br J Exp Pathol       Date:  1986-10

6.  Characterization of neuraminidases produced by various serotypes of group B streptococci.

Authors:  J G Brown; D C Straus
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

7.  Effects of group B Streptococcus toxin on long-term survival of mice bearing transplanted Madison lung tumors.

Authors:  G B Thurman; B A Russel; G E York; Y F Wang; D L Page; H W Sundell; C G Hellerqvist
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  Antitumor effects of GBS toxin: a polysaccharide exotoxin from group B beta-hemolytic streptococcus.

Authors:  C G Hellerqvist; G B Thurman; D L Page; Y F Wang; B A Russell; C A Montgomery; H W Sundell
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

9.  Molecular basis for group B beta-hemolytic streptococcal disease.

Authors:  C G Hellerqvist; H Sundell; P Gettins
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

10.  CM101-mediated recovery of walking ability in adult mice paralyzed by spinal cord injury.

Authors:  A W Wamil; B D Wamil; C G Hellerqvist
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.